NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Phase 2
Completed
- Conditions
- Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 116
- Registration Number
- NCT00085371
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00085111
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Completed
- Conditions
- Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Gastric CancerStage IIIA Gastric CancerStage IIIB Gastric CancerStage IIIC Gastric CancerStage IV Gastric Cancer
- Interventions
- Biological: bevacizumabProcedure: computed tomographyOther: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT00084604
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Phase 2
Terminated
- Conditions
- Localized Unresectable Adult Primary Liver CancerAdvanced Adult Primary Liver CancerGastrointestinal CancerAdenocarcinoma of the Extrahepatic Bile DuctRecurrent Adult Primary Liver CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerAdenocarcinoma of the GallbladderRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder Cancer
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00085410
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00084877
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
Phase 1
Completed
- Conditions
- Recurrent Colon CancerRecurrent Rectal CancerStage IIIC Colon CancerStage IIIC Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: GTI-2040Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-03-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00084643
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
Phase 2
Completed
- Conditions
- Adult FibrosarcomaDermatofibrosarcoma ProtuberansRecurrent Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00084630
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 3
Completed
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Secondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Untreated Adult Acute Myeloid Leukemia
- Interventions
- Biological: oblimersen sodiumOther: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 500
- Registration Number
- NCT00085124
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Phase 2
Completed
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Blastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Previously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesRecurrent Adult Acute Lymphoblastic LeukemiaSecondary Myelodysplastic Syndromes
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00084916
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Phase 1
Completed
- Conditions
- Adult Anaplastic AstrocytomaAdult GliosarcomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaRecurrent Adult Brain Tumor
- Interventions
- Drug: depsipeptide
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00085540
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States